Replies to post #751 on Lineage Cell Therapeutics Inc (LCTX)

[terry hallinan]

OpRegen is the nearest catalyst and has incredible upside, and Biotime management wisely does not want to dilute its holding in this very promising platform product.

DeepDive,

I tend to agree with most of your speculation except I fear you may be a bit too optimistic about a speedy path to approval.

Dry AMD, as opposed to wet AMD, is very slow in developing which may be part of the explanation for why there has never been an approved treatment for over 3/4's of the form of AMD causing blindness in the aged.

That means that obtaining proof of efficacy can take many years unless valid indices of efficacy can be developed.

In spite of that, OpRegan could have speculative juices flowing if there were any appetite today for such as banishing most blindness of the aged but there is precious little of that in our deeply frightened populace and markets.

IMO Dr. West has shown phenomenal skill in fundraising for his futuristic projects.

JMO.

Best, Terry

[Cincinnatus]

I fail to see how OpRegen can be the "nearest catalyst"?? I'm not going to rehash the last conference call, but it seems the opening comments clearly pointed to the likelihood of Renevia being the lead possibility to affect the share price.

For that matter if the Q1/18 results from AST's spinal study were to be positive and gain more media coverage...and RMAT boost to approval, that could be a tremendous boost to both AST and BTX.

If I'm missing something about OpRegen's likely path to being a near term catalyst, please explain.